• Users Online: 421
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 4  |  Issue : 2  |  Page : 50-54

Effect of conbercept or ranibizumab in the treatment of wet age-related macular degeneration


1 Department of Ophthalmology, Beijing Luhe Hospital, Capital Medical University, Beijing, China
2 Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA
3 Department of Nephrology, Beijing Luhe Hospital, Capital Medical University, Beijing, China

Correspondence Address:
Dr Tao Chai
82 Xinhua South Road, Tongzhou District, Beijing
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ed.ed_5_19

Rights and Permissions

Objective: The aim of this study was to investigate the effects of conbercept or ranibizumab in the treatment of wet age-related macular degeneration(AMD) and to explore the influence on central retinal thickness (CRT), visual acuity, and choroidal neovascularization(CNV) permeation. Patients and Methods: Atotal of 85patients(85 eyes) with wet AMD were enrolled in this study. All patients were treated by intravitreal injection of anti-vascular endothelial growth factor and were randomly divided into two groups. Patients in GroupA were treated by intravitreal injection of conbercept, whereas those in GroupB were treated by intravitreal injection of ranibizumab once a month for 3 consecutive months. The best-corrected visual acuity(BCVA) was measured. Subfoveal choroidal thickness(SFCT) and CRT of affected eyes and healthy eyes were examined with optical coherence tomography. Fundus fluorescein angiography was performed, and the area of CNV permeation was calculated. Results: BCVA(logarithm of the minimum angle of resolution) of affected eyes in the two groups was significantly better at 1month, 2months, and 3months after treatment as well as at the end of follow-up than that of before treatment. Meanwhile, CRT was obviously decreased. SFCT of affected eyes was significantly smaller than that of before treatment, which was also remarkably smaller when compared with that of healthy eyes. At 3months after treatment and at the end of follow-up, the areas of CNV permeation in the two groups were significantly decreased. In addition, the average times of injection in GroupA were significantly less than that of GroupB. Conclusions: Intravitreal injection of conbercept and ranibizumab significantly decreased SFCT of affected eyes. However, the length of conbercept medication injection time was lower than that of ranibizumab.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2141    
    Printed131    
    Emailed0    
    PDF Downloaded208    
    Comments [Add]    

Recommend this journal